175 related articles for article (PubMed ID: 37430022)
1. Integrated analyses reveal the prognostic, immunological features and mechanisms of cuproptosis critical mediator gene FDX1 in KIRC.
Wang Y; Zhang X; Chen G; Xing Q; Zhu B; Wang X
Genes Immun; 2023 Aug; 24(4):171-182. PubMed ID: 37430022
[TBL] [Abstract][Full Text] [Related]
2. Multi-omics pan-cancer study of cuproptosis core gene
Xu J; Hu Z; Cao H; Zhang H; Luo P; Zhang J; Wang X; Cheng Q; Li J
Front Immunol; 2022; 13():981764. PubMed ID: 36605188
[TBL] [Abstract][Full Text] [Related]
3. Cuproptosis-related gene FDX1 as a prognostic biomarker for kidney renal clear cell carcinoma correlates with immune checkpoints and immune cell infiltration.
Yao Y; Chen H; Lou M; Chen T
Front Genet; 2023; 14():1071694. PubMed ID: 36755576
[No Abstract] [Full Text] [Related]
4. Cuproptosis status affects treatment options about immunotherapy and targeted therapy for patients with kidney renal clear cell carcinoma.
Zhang G; Chen X; Fang J; Tai P; Chen A; Cao K
Front Immunol; 2022; 13():954440. PubMed ID: 36059510
[TBL] [Abstract][Full Text] [Related]
5. Cuproptosis-related gene
Wang T; Liu Y; Li Q; Luo Y; Liu D; Li B
Front Immunol; 2022; 13():999823. PubMed ID: 36225932
[TBL] [Abstract][Full Text] [Related]
6. Pan-cancer integrated bioinformatics analysis reveals cuproptosis related gene FDX1 is a potential prognostic and immunotherapeutic biomarker for lower-grade gliomas.
Huang W; Wu Y; Zhu J; Luo N; Wang C; Liu S; Cheng Z
Front Mol Biosci; 2023; 10():963639. PubMed ID: 36825202
[TBL] [Abstract][Full Text] [Related]
7. The potential of targeting cuproptosis in the treatment of kidney renal clear cell carcinoma.
Lei G; Tang L; Yu Y; Bian W; Yu L; Zhou J; Li Y; Wang Y; Du J
Biomed Pharmacother; 2023 Nov; 167():115522. PubMed ID: 37757497
[TBL] [Abstract][Full Text] [Related]
8. Elevated ADH5 expression suggested better prognosis in kidney renal clear cell carcinoma (KIRC) and related to immunity through single-cell and bulk RNA-sequencing.
Sun J; Zhang X; Wu F; Zhu B; Xie H
BMC Urol; 2024 Apr; 24(1):84. PubMed ID: 38600527
[TBL] [Abstract][Full Text] [Related]
9. Survival Prognosis, Tumor Immune Landscape, and Immune Responses of PPP1R18 in Kidney Renal Clear Cell Carcinoma and Its Potentially Double Mechanisms.
Wang Y; Liu S; Chen Y; Zhu B; Xing Q
World J Oncol; 2022 Feb; 13(1):27-37. PubMed ID: 35317332
[TBL] [Abstract][Full Text] [Related]
10. Pan-cancer analyses confirmed the cuproptosis-related gene FDX1 as an immunotherapy predictor and prognostic biomarker.
Zhang C; Zeng Y; Guo X; Shen H; Zhang J; Wang K; Ji M; Huang S
Front Genet; 2022; 13():923737. PubMed ID: 35991547
[No Abstract] [Full Text] [Related]
11. A cuproptosis-related gene signature and associated regulatory axis in stomach adenocarcinoma based on bioinformatics analysis.
Ding D; Wang D; Qin Y
Medicine (Baltimore); 2023 Jul; 102(30):e34230. PubMed ID: 37505170
[TBL] [Abstract][Full Text] [Related]
12. A novel signature to guide osteosarcoma prognosis and immune microenvironment: Cuproptosis-related lncRNA.
Yang M; Zheng H; Xu K; Yuan Q; Aihaiti Y; Cai Y; Xu P
Front Immunol; 2022; 13():919231. PubMed ID: 35967366
[TBL] [Abstract][Full Text] [Related]
13. High expression of cuproptosis-related gene FDX1 in relation to good prognosis and immune cells infiltration in colon adenocarcinoma (COAD).
Wang L; Cao Y; Guo W; Xu J
J Cancer Res Clin Oncol; 2023 Jan; 149(1):15-24. PubMed ID: 36173462
[TBL] [Abstract][Full Text] [Related]
14. Elevated PTTG1 predicts poor prognosis in kidney renal clear cell carcinoma and correlates with immunity.
Zhang X; Ji H; Huang Y; Zhu B; Xing Q
Heliyon; 2023 Feb; 9(2):e13201. PubMed ID: 36793955
[TBL] [Abstract][Full Text] [Related]
15. Cuproptosis-related modification patterns depict the tumor microenvironment, precision immunotherapy, and prognosis of kidney renal clear cell carcinoma.
Cai Z; He Y; Yu Z; Hu J; Xiao Z; Zu X; Li Z; Li H
Front Immunol; 2022; 13():933241. PubMed ID: 36211378
[TBL] [Abstract][Full Text] [Related]
16. Molecular subtypes based on cuproptosis regulators and immune infiltration in kidney renal clear cell carcinoma.
Liu A; Li Y; Shen L; Li N; Zhao Y; Shen L; Li Z
Front Genet; 2022; 13():983445. PubMed ID: 36338990
[TBL] [Abstract][Full Text] [Related]
17. Prognostic, Clinicopathological, and Function of Key Cuproptosis Regulator
Zeng S; Zhang H; Zhang D; Hu X; Song L
Genes (Basel); 2022 Sep; 13(10):. PubMed ID: 36292610
[TBL] [Abstract][Full Text] [Related]
18. A Novel Cuproptosis-Related Prognostic Model and the Hub Gene
Zhang K; Yang W; Zhang Z; Ma K; Li L; Xu Y; Qiu J; Yu C; Zhou J; Cai L; Gong Y; Gong K
J Oncol; 2022; 2022():2124088. PubMed ID: 36536785
[TBL] [Abstract][Full Text] [Related]
19. Confirmation of the predictive function of cuproptosis-related gene FDX1 in clear cell renal carcinoma using qRT-PCR and western blotting.
Cai C; Zhou K; Jing J; Ren Y; Weng G; Cen D; Wang X; Huang S
Aging (Albany NY); 2023 Jul; 15(13):6117-6134. PubMed ID: 37432054
[TBL] [Abstract][Full Text] [Related]
20. Identification and Validation of Cuproptosis-Related LncRNA Signatures in the Prognosis and Immunotherapy of Clear Cell Renal Cell Carcinoma Using Machine Learning.
Bai Z; Lu J; Chen A; Zheng X; Wu M; Tan Z; Xie J
Biomolecules; 2022 Dec; 12(12):. PubMed ID: 36551318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]